HepaSmart
AI
AI-powered liver disease intelligence
A specialised AI-driven hepatology platform providing clinicians with structured tools for liver disease staging, fibrosis assessment, hepatitis management, and evidence-based treatment pathway navigation.
Liver Disease Is Vastly
Underdiagnosed
Liver disease management requires integrating complex biochemical, histological, and clinical data across multiple scoring systems. Errors in fibrosis staging or delayed treatment initiation significantly worsen patient prognosis — and the tools to prevent this are scattered and difficult to access.
Most general practitioners lack the structured hepatology framework needed to identify at-risk patients early. By the time liver disease is discovered, fibrosis is often advanced — and the window for effective intervention has narrowed.
25%
of adults globally have NAFLD — most undiagnosed
70%
of NASH patients have no symptoms until advanced disease
Without structured hepatology decision tools, fibrosis progression to cirrhosis is frequently missed until irreversible end-stage disease has developed.
One Platform. Complete Hepatology Intelligence.
HepaSmart AI brings structure to the complexity of liver disease management through three core pillars
Assess & Stage
Input patient biochemistry data to instantly calculate validated scores — MELD, Child-Pugh, FIB-4, APRI — with automated interpretation and severity classification.
Navigate Pathways
Access structured management protocols for each liver condition — NAFLD, viral hepatitis B and C, cirrhosis — aligned with AASLD and EASL 2023 guidelines.
Prevent & Surveil
Generate personalised surveillance schedules for HCC, variceal screening intervals, and complication monitoring timelines to prevent disease progression.
Key Features & Capabilities
Multi-Score Hepatology Suite
MELD, Child-Pugh, FIB-4, and APRI scoring tools in a single integrated interface with instant result interpretation and clinical guidance.
NAFLD & NASH Assessment
Structured non-alcoholic fatty liver disease staging with lifestyle intervention recommendations, fibrosis risk stratification, and pharmacotherapy guidance.
Viral Hepatitis Pathways
Evidence-based management protocols for chronic Hepatitis B and C — from initial assessment to antiviral therapy eligibility and monitoring schedules.
Cirrhosis Complication Screening
Systematic screening protocols for variceal bleeding risk, hepatic encephalopathy, spontaneous bacterial peritonitis, and hepatorenal syndrome.
Liver Cancer Surveillance
HCC surveillance interval guidance based on fibrosis stage and aetiology, aligned with AASLD and EASL imaging recommendation timelines.
Treatment Eligibility Pathways
Decision support for DAA therapy in HCV, HBV antiviral initiation thresholds, NAFLD pharmacotherapy criteria, and transplant referral triggers.
Clinical Scoring Tools in Action
Explore how each validated scoring tool works — click the tabs below to switch between MELD, Child-Pugh, FIB-4, and APRI calculators
Model for End-Stage Liver Disease
AASLD / EASL Guidelines 2023
Predicts 90-day mortality in chronic liver disease and prioritises liver transplant allocation
Sample Input Values
Note: Values shown are illustrative examples. Always input patient-specific data for accurate clinical assessment.
Calculated Result
Clinical Interpretation
10–19: ~6% 90-day mortality. Regular monitoring and transplant evaluation recommended.
Recommended Action
Refer for transplant workup
Sample values for demonstration only. All calculations follow validated formulas aligned with AASLD and EASL 2023 guidelines.
15 Liver Conditions Covered
HepaSmart AI covers the full spectrum of liver pathology encountered in clinical practice — from early-stage NAFLD to advanced cirrhosis and HCC surveillance.
All pathways are based on AASLD, EASL, and WHO clinical practice guidelines updated to 2023–2024.
Designed for Clinical Professionals
Hepatologists
Streamline complex liver disease workups and access all scoring tools in one place.
Gastroenterologists
Manage liver disease alongside GI conditions with integrated decision support.
General Physicians
Confidently screen and refer patients with suspected liver pathology.
Medical Residents
Learn hepatology management frameworks grounded in current evidence.
Why Hepatology Intelligence Matters
The scale of liver disease demands proactive, structured clinical responses
25%
Adults globally have NAFLD
Most remain undiagnosed
2M+
Annual liver disease deaths
Largely preventable with early detection
80%
HCC cases linked to cirrhosis
Surveillance saves lives
6
Core scoring tools
Validated by AASLD & EASL
Educational & Decision Support Tool Only. HepaSmart AI is designed to support clinical decision-making and is not a substitute for professional medical judgement, specialist consultation, or patient-specific clinical evaluation. Always apply results within the full clinical context.
Ready to Enhance Your Hepatology Practice?
HepaSmart AI is currently in Beta. Join our early access programme and help shape the future of AI-powered liver disease intelligence.